US-based CDMO Catalent has agreed to acquire Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support (SCTS), in Gosselies, Belgium, for...
US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood...
Catalent Gene Therapy, a unit of US-based CDMO Catalent, is spending $130 million on five new Phase 3-through commercial-scale manufacturing suites at its gene therapy...
Catalent Biologics is investing $50 million in an additional high-speed vial filling line at its Bloomington, Indiana, USA, facility to support the growing pipeline of...
Catalent Cell & Gene Therapy, a unit of US-based CDMO Catalent, has signed on to provide drug substance manufacturing to AstraZeneca for the University of Oxford’s...
US biotechs Catalent and Humanigen are extending their standing collaboration on lenzilumab, Humanigen’s proprietary anti-human granulocyte macrophage-colony stimulating...
US-based CDMO Catalent has agreed a collaboration with US biotech Moderna for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine...
